usf health yrd alzheimer [s institute page 1/media/files/byrd... · usf health yrd alzheimer [s...

U S F H e a l t h B y r d A l z h e i m e r ’ s I n s t i t u t e


Contents

Letter from the Chief Executive Officer 3

Faculty Appointed to the institute 4

Statistics 6

2012 Financial Overview 7

Research 9

Alzheimer’s Clinical Center 13

Education 15

Business Operations 20

Development 23

Faculty Achievement 24

Faculty & Staff News Media 29

About the USF Health Byrd Alzheimer’s Institute

The USF Health Byrd Alzheimer's Institute was founded in 2002 on the vision of former Florida Speaker of the House, Johnnie Byrd, Jr. whose father suffered from Alzheimer’s disease and for a number of years was known as the Johnnie B. Byrd, Sr. Alzheimer’s Center and Research Institute. Today the institute is a multi-disciplinary center of excellence at the University of South Florida that provides compassionate family-centered patient care, performs cutting edge research and delivers quality public and professional education. With a state-of-the-art building and a highly qualified team of researchers, doctors, clinicians and educators, the institute is at the forefront of Alzheimer's research and care. Mission Statement The USF Health Byrd Alzheimer’s Institute is dedicated to the prevention, treatment and cure of Alzheimer’s disease and related disorders.

The key activities of the institute include: Conducting laboratory research to

understand the changes in the brain that cause dementia and to develop approaches for the prevention and treatment of Alzheimer's disease.

Conducting clinical trials to test treatments for individuals with all stages of memory loss.

Providing state-of-the-art diagnostic evaluations and the highest level of patient care to individuals with Alzheimer's disease and other memory problems.

Supporting family caregivers by providing educational programs, support groups, counseling and information.

Providing education and training for healthcare professionals, service providers and students.


Letter from the Chief Executive Officer

Welcome to the Byrd Institute Annual Report for the 2013-14 fiscal year. This year witnessed several changes in the institute, and the initiation of several new programs. We have opened and entirely new service line for both the institute and for USF, in Occupational Therapy. Since opening last fall, we have had roughly 250 visits for services in the multiple activities provided through the Functional Assessments Facility. Visits will continue to grow as awareness about these services spreads within USF Health. We continued to expand our existing program in Community Based Memory Screening to East Tampa, and we are adding another educator to our staff to spread this program throughout the state. We also now offer a membership program referred to as Priority Memory Care. The membership fee for this program provides patients and their families with rapid medical appointments bundled with new and existing services.

In the past year one of our Suncoast physicians retired, and the Geriatrician seeing patients in the C.A.R.E. center left the university. In addition, the Dept. of Psychiatry Memory Disorders Clinic moved out of the building to achieve a less expensive “rent” paid to the practice plan. As a result, total patient visits declined slightly. Moving forward we intend to replace the physicians and will try to bring the Psychiatry clinic back into the institute.

The Byrd Institute has been “discovered” by the undergraduate students. The number of USF students quintupled over the last 2 years, nearing 100. Undergraduate volunteers provide invaluable services in the research laboratories, while receiving training in biomedical research. For many, the greatest reward is a strong recommendation to graduate or medical school. This rise in volunteers was coupled with declines in other staff numbers, primarily technical staff in the laboratories. Notably, our development officer was promoted to a new position, thus we are recruiting a staff person to fill that position.

Total expenditures and funding for the institute declined about 10% last year. This was largely due to reduced NIH grant funding associated with Federal budget sequestration. One large Dept. of Defense grant was discontinued due to sequestration, and new grants from NIH were elusive, at best. Overall the decrease in Federal support was $1.5 million. Our Grants Assistance Committee, a panel of experienced investigators who review grant ideas and projects before they are submitted, has redoubled its efforts. Already in the 2014-15 fiscal year we are seeing increases in new grant funding. We hope to continue this positive trend for the remainder of the year.

Although total patient visits were down, clinical revenue increased slightly. This was due to a continued increase in the number of PET scans being performed. The volume in the Pfeifer Imaging Center increased sufficiently to necessitate hiring a second PET technologist to continue expanding this service line. The clinical research activities increased slightly and expanded with the hire of a new clinical trial coordinator. A number of new clinical trial contracts have been received in the recent past and this activity appears to be expanding again.

We continued our arrangement with an outside lobbying team and the University of Florida to educate the

legislature regarding the value of investing in Alzheimer’s research. This led to each University receiving $1.25

million again for 2014-15 to expand Alzheimer’s disease research programs. Our goal this year is to work

through the USF legislative team to obtain this funding as a recurring item for the 2015-16 university budget.

Dave Morgan, PhD ...until Alzheimer’s is a memory®

CEO and Executive Director


Faculty Appointed to the USF Health Byrd Alzheimer’s Institute

Jessica L. Banko, Ph.D., M.S. Associate Professor of Molecular Medicine College of Medicine Deborah Burke, M.D. Assistant Professor of Neurology College of Medicine Chuanhai Cao, Ph.D. Assistant Professor of Pharmaceutical Sciences College of Pharmacy Hemant Chheda, M.D. Assistant Professor of Radiology College of Medicine Chad Dickey, Ph.D. Associate Professor of Molecular Medicine College of Medicine Michelle Estevez, M.D. Assistant Professor of Internal Medicine College of Medicine Kristin Fargher, M.D. Assistant Professor of Psychiatry & Behavioral Neurosciences College of Medicine Jean M. Fils, MD. Assistant Professor of Psychiatry & Behavioral Neurosciences College of Medicine Joshua Gamsby, PhD. Research Associate, Byrd Institute College of Medicine Marcia Gordon, Ph.D. Professor of Molecular Pharmacology & Physiology College of Medicine

Danielle Gulick, Ph.D. Assistant Professor of Molecular Medicine College of Medicine Robert Hauser, M.D., M.B.A. Professor of Neurology College of Medicine Angela Hill, Pharm.D., BCPP Professor & Chair, Pharmacy Practice College of Pharmacy David Kang, Ph.D. Associate Professor of Molecular Medicine College of Medicine Umesh Jinwal, Ph.D. Assistant Professor of Pharmaceutical Sciences College of Pharmacy Daniel Lee, Ph.D. Assistant Professor of Pharmaceutical Sciences College of Pharmacy Michelle L. Mattingly, Ph.D., A.B.P.P.-C.N. Assistant Professor of Psychiatry & Behavioral Neurosciences College of Medicine

David G. Morgan, Ph.D. Distinguished Professor of Molecular Pharmacology & Physiology College of Medicine Peter Mouton, Ph.D. Professor of Pathology & Cell Biology College of Medicine Kevin Nash, Ph.D. Assistant Professor of Molecular Pharmacology & Physiology College of Medicine


Jaya Padmanabhan, Ph.D. Assistant Professor of Molecular Medicine College of Medicine Eileen Poiley, M.S. Associate of Suncoast Gerontology College of Medicine Balaibail Ashok Raj, M.D. Professor of Neurology College of Medicine Michael R. Schoenberg, Ph.D., A.B.P.P.-C.N. Associate Professor of Psychiatry & Behavioral Neurosciences College of Medicine

Maj-Linda Selenica, Ph.D. Assistant Professor of Pharmaceutical Sciences College of Pharmacy

Amanda G. Smith, M.D. Associate Professor of Psychiatry & Behavioral Neurosciences College of Medicine Jill Smith, M.S. Instructor School of Aging Studies Nancy Teten, L.C.S.W. Instructor of Neurology College of Medicine Edwin J. Weeber, Ph.D. Associate Professor of Molecular Pharmacology & Physiology College of Medicine

Associate Members

Ross Andel, Ph.D. Associate Professor of School of Aging Studies College of Behavioral & Community Sciences Jennifer Lister, Ph.D., CCC-A, FAAA Associate Professor College of Behavioral & Community Sciences Aryn Bush, Ph.D. Assistant Professor of School of Aging Studies College of Behavioral & Community Sciences Alyssa Gamaldo, Ph.D. Assistant Professor of School of Aging Studies College of Behavioral & Community Sciences Vladimir Uversky, Ph.D., DSc Associate Professor of Molecular Medicine College of Medicine Jerri Edwards, Ph.D. Associate Professor of School of Aging Studies College of Behavioral & Community Sciences

Paula Bickford, Ph.D. Professor of Center of Excellence for Aging & Brain Repair College of Medicine Brent Small, Ph.D. Professor of School of Aging Studies College of Behavioral & Community Sciences Meredeth Rowe, RN, Ph.D., FGSA, FAAN Professor and Endowed Chair College of Nursing Kevin Kip, Ph.D., FAHA Distinguished Professor College of Nursing Eric Pfeiffer, M.D. Professor Emeritus of Psychiatry & Behavioral Neurosciences College of Medicine Shaui Huang, Ph.D Assistant Professor of Industrial Engineering College of Engineering


USF Health Byrd Alzheimer’s Institute Statistics

2011/2012

2012/2013

2013/2014

CLINIC

Suncoast Alzheimer's Center new patient visits 386 329 529

Suncoast Alzheimer's Center Follow-up visits 1,388 1,679 1,489

C.A.R.E. visits (opened Feb 2012) 104 187 262

Imaging visits (opened Jan 2012, diagnostic) 100 251 289

Occupational Therapy visits (opened Sept 2013) - - 203

Driver Safety Evaluations (opened Sept 2013) - - 44

Clinical Trial visits 654 200 274

Memory Disorders Clinic visits (closed Oct 2013) 1228 941 73

Movement Disorders Clinic visits (opened 2012) 1450 2158 2450

Geriatric Medicine visits 279 380 518

Total patient visits 5,589 6,125 6,131

STUDENTS

Medical degree-seeking (program ended 2012) 19 - 3

Graduate degree-seeking 34 33 35

Post-doctoral 17 20 15

Undergraduate 20 63 97

High School 4 15 13

Total Trainees 94 132 163

FACULTY AND STAFF

Clinical Faculty 15 14 12

Clinical Staff 21 20 17

Laboratory Research Faculty 13 15 14

Laboratory Research Staff 28 24 14

Education Faculty 1 1 1

Administrative Staff 7 7 6

Plant Operations/Maintenance Staff 5 5 6

Part-time/temporary Staff 1 1 2

Total Employees 91 87 71

RESEARCH

Active Research Grants 39 35 26 Active Clinical Trials 13 10 14

Clinical Trial Subject Visits 654 200 274

ENDOWMENT

Principal Value $ 4,616,579 $ 5,386,509 $ 5,478,384

Market Value $ 5,517,597 $ 6,697229 $ 7,643,015


2014 Financial Overview

Funding by Source

Expenditures by Activity

8% PSR

28% Basic Research Grants

5% Institute Reserves

6% Clinical Research Grants

43% E&G

4% USF 1% EBA

6% Foundation

47% Research

13% Clinical Services

15% Education

1% Development 2% External Affairs

5% Business Operations

17% Facility Operations/

Maintenance


Funding by Source (in thousands) 2011/2012 2012/2013 2013/2014

$ $ $

Basic Research Grants 4,390

3,650 2,365

Clinical Research Grants 460 587 533

USF Foundation 564 356 478

E&G 2,554 2,845 3,690

Patient Services Revenue 310 641 671

Educational Business Activity (est. 2012)

39

28 43

USF

373

591 374 Institute Reserves 1,749 1,040 404

TOTAL INSTITUTE FUNDING

10,439

9,738 8,558

Expenditures by Activity (in thousands) 2011/2012 2012/2013 2013/2014

Total Total Total

$ $ $

RESEARCH EXPENDITURES 5,912 5,117 4,016

Federal Grants 3,831 2,711 1,297

Non-Federal Grants 559 939 1,068

Alzheimer Institute 319 186 61

USF 373 591 373

USF Foundation 360 165 169

Clinical Trials 470 525 553 State Appropriation (first received 2014) 495

CLINICAL SERVICES EXPENDITURES 907 1,209 1,131

EDUCATIONAL EXPENDITURES 802 1,024 1,265

Faculty E&G 692 911 1,137

Caregiving and Professional Education 110 114 128

DEVELOPMENT EXPENDITURES 133 133 101

EXTERNAL AFFAIRS EXPENDITURES 285 253 164

BUSINESS OPERATIONS EXPENDITURES 530 431 421

Finance and Accounting 121 121 76

USF Health Governance 169 38 59

Executive Administration 240 272 286

FACILITY OPERATION & MAINTENANCE 1,870 1,571 1,460

TOTAL INSTITUTE EXPENDITURES 1,0439 9,738 8,558


Research

Clinical Research

We recognize the critical need to research new treatment options. Current medications cannot stop Alzheimer’s disease. These medications may help prevent some symptoms from getting worse. Current research is aiming to halt or slow the progression of Alzheimer’s disease itself. Additionally, there is a great need for better ways to diagnosis and treat memory problems earlier. Our center is involved in a number of research studies for various stages of Alzheimer’s disease and mild cognitive impairment. Several of these studies investigate potential treatments that target the plaques and tangles in the brain. Some studies involve pills, while others use intravenous infusions or injections. Other trials study the effect of noninvasive treatments and nutritional supplements on Alzheimer’s disease. Some of our studies involve more advanced brain imaging techniques such as PET scans. Many of these trials are part of the Alzheimer’s Disease Collaborative Study (ADCS), or the Alzheimer’s Disease Neuroimaging Initiative, both NIH funded nationwide clinical research consortia of leading Alzheimer’s research centers. In addition, we continue to enroll subjects in our pilot study of coconut oil as a symptomatic treatment for AD. While we had a slow fiscal year in 2013, this 2014 fiscal year has been very productive! Not only have we continued participation in trials to target beta amyloid in mild to moderate Alzheimer’s disease and mild cognitive impairment, we’ve also become more involved in other areas of clinical research. This year we began a trial investigating a treatment for the tau protein that causes tangles. We were also selected as a site for new PET scan imaging agents that are in development for an imaging agent to detect and measure this tau protein as well to begin enrollment in FY 2015. (An agent called Amyvid™ was FDA-approved in 2012 to detect and measure amyloid plaques.) And lastly, we were selected as one the sites in the US, Canada, and Australia to participate in a new, innovative prevention trial funded by Eli Lilly and the NIH for people who are over the age of 65 and may be at risk for developing Alzheimer’s disease called the A4 trial, as well as another trial investigating a new innovative treatment approach using nasal insulin spray for patients with mild cognitive impairment and mild Alzheimer’s disease. With great optimism, we look forward to the next year of research. We will be busy enrolling and continuing trials, as well as bringing on new staff to support in the increased activity.

Clinical Research Statistics

2011/2012 2012/2013 2013/2014

New studies awarded 2 2 6

Active studies 13 10 15

Enrolling studies 6 4 10

Total subjects enrolled 30 21 108

Subject visits 654 200 349

Average enrollment per trial 9 9 9

Average enrollment fulfillment (# screened/# contracted) 153% 100% 69%

Average randomized success (# randomized/#screened) 92% 82% 82%

Research study income (direct costs) $ 459,825 $ 587,453 $ 533,152 Research study expenses (direct costs) $ 469,927 $ $524,853 $ 513,304


Studies active during fiscal year 2014 listed by study sponsor

1. ADCS: Alzheimer’s Disease Neuroimaging Initiative (ADNI2) A nationwide study to collect information about individuals using MRI, PET scan, spinal fluid, cognitive status, blood biomarkers over multiple years to form a database of information on the course of aging and Alzheimer’s disease [PI: Smith]

2. ADCS: Anti Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study). (H8A-MC-LZAZ/A4) [PI: Smith]

3. ADCS: Phase II Study to Evaluate the Impact on Biomarkers of Resveratrol Treatment in Patients with Mild to Moderate Alzheimer’s Disease.

4. ADCS: Therapeutic effects of intranasally-administered insulin (INI) in adults with amnestic mild cognitive impairment (aMCI) or mild Alzheimer’s disease (AD). (ADC-046-INI) [PI: Smith]

5. Avid: An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with Mild Cognitive Impairment, and subjects with Alzheimer’s disease (18F-AV-1451-A05) [PI: Smith]Dana Foundation: Safety, Efficacy of GM-CSF (Leukine) For Treatment of Alzheimer's Disease [PI: Potter, Raj]

6. Dana Foundation: Safety, Efficacy of GM-CSF (Leukine) for Treatment of Alzheimer’s Disease [PI: Raj] 7. Eisai: A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomized Design and Dose

Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects with Early Alzheimer's Disease (BAN2401-G000-201) [PI: Smith]

8. Eli Lilly: Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid Beta Antibody in Patients with Alzheimer’s Disease (H8A-MC-LZAO) [PI: Raj]

9. Eli Lilly: Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) Versus Placebo. (H8A-MC-LZAX) [PI: Raj]

10. Janssen: A Phase II, Twenty-Four Month, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Amyloid-Imagine Positron Emission Tomography (PET) and Safety Study of ACC-001 and QS-21 adjuvant in subjects with mild to moderate Alzheimer’s disease. (ACC-001-ALZ-2001) [PI: Smith]

11. Merck: A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer’s Disease. (Protocol No. MK-8931-017) [PI: Smith]

12. Merck: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the

Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment Due to

Alzheimer’s Disease (Prodromal AD). (MK-8931-019) [PI: Smith]

13. TauRx: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study

of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild Alzheimer’s Disease (TRx-237-

005) [PI: Raj]

14. USF and Leo and Anne Albert Charitable Trust: A Randomized, Double-Blind, Placebo-Controlled, 6 Month

Cross-Over Study to Evaluate the Efficacy of Coconut Oil (Fuel for Thought™) Treatment for Subjects with

Mild to Moderate Alzheimer’s Disease [PI: Smith]

15. Foundation for Angelman Syndrome Therapeutics: The effects of minocycline in the treatment of Angelman

syndrome. [PI: Weeber]


Basic and Translational Research

The Discovery Research Laboratories within the USF Health Byrd Alzheimer's Institute are engaged in basic and

translational research aimed at understanding the patho-physiology of Alzheimer’s disease with a focus on

developing new therapeutics to prevent, treat and cure the disease. Complimentary programs in other

neurodegenerative diseases, neurodevelopmental disorders and bioengineering have also emerged within

several laboratories in recent years. These programs diversify the institute’s sponsored research funding

portfolio, and more importantly, expand the breadth and impact of the institute’s scholarly activities and

contributions.

The funding portfolio of newly awarded research grants to Institute investigators changed dramatically last fiscal

year. No new NIH awards were received by Institute investigators in 2014 and the Department of Defense

continuing program awarded in 2011 was eliminated as a result of the Sequestration Act. The private funding

sector has largely absorbed the research funding burden levied by the dramatic federal program spending cuts

and sequestration. Recognizing the change in tide, Institute faculty aggressively pursued foundation- and

industry-sponsored funding opportunities. Whether the private sector will continue to be in a position to

support research at the current level is unpredictable. Investigators continue efforts to diversify their sources of

research income to fund their programs. These efforts chiefly include cultivating new multidisciplinary

partnerships with industry, intellectual property development and increased emphasis on foundation and

philanthropy support. We have also formalized a program for review of grant applications from Institute faculty

by senior researchers in the institute.

During 2014, Institute researchers have shared their research findings with the academic community during 43

invited presentations, at 23 scientific conferences and through 28 peer-reviewed journal articles.

Basic and Translational Sponsored Research Statistics

2011/2012 2012/2013 2013/2014

New federal grants 6 3 1

Continuing federal grants 16 12 7

New non-federal grants 5 9 4

Continuing non-federal grants 12 9 8

Total active grants 39 33 20

Research faculty/Principal Investigators

14

15 14

Average sponsored activity per research faculty

2.8

2.2 1.4

New federal grant awards value ( annualized) $ 1,376,681 $ 306,548 74,750

New non-federal grant awards value (annualized) $ 429,778 $ 1,391,595 356,539

Total new grant award value $ 1,806,459 $ 1,718,143 431,289

Federal grant expenditures $ 3,831,029 $ 2,710,953 1,296,822

Non-federal grant expenditures $ 558,846 $ 939,336 1,068,257

Total sponsored research expenditures $ 4,389,875 $ 3,650,289 2,365,079


Grants active during fiscal year 2013 listed by sponsor

Federal Sponsors

1. National Institute of Aging “ApoE receptor biology and neurodegeneration” [PI: Weeber] 2. National Institute of Aging “ApoE effects on neuron signaling and function via ApoER2" [PI: Weeber] 3. National Institute of Aging “Novel Mechanisms of RanBP9 in APP Pathogenesis” [PI: Kang] 4. National Institute of Aging “Chemical Probes and Chaperone-Accelerated Turnover of Tau” [PI: Dickey] 5. National Institute of Neurological Disease and Stroke “The Hsp90 cochaperone FKBP51 regulates tau

structure and function” [PI: Dickey] 6. National Institute of Neurological Disease and Stroke “Inhibition of Hsp70 ATPase activity” [PI: Dickey] 7. National Institute of Neurological Disease and Stroke “Immunotherapy against tauopathy in a

transgenic mouse model” [PI: Morgan] 8. Veterans Administration Medical Center - James A. Haley “HSP70/DNAJ interface as a drug target for

Alzheimer’s disease and TBI” [PI: Dickey]

Non-Federal Sponsors

1. ALS Biopharma “A Diarylheptanoid scaffold to treat tauopathies” [PI: Dickey] 2. Alzheimer’s Association “Ketogenesis and Alzheimer Pathology” [PI: Morgan] 3. Alzheimer's Association “Impact of Arginase-1 Deficiency on Tau and Amyloid Pathogenesis” [PI: Lee] 4. American Health Assistance Foundation “Disrupting Chaperone/Myocilin Complexes for Glaucoma” [PI:

Dickey] 5. American Health Assistance Foundation “Chemical Approaches to Reducing Tau Levels” [PI: Dickey] 6. American Federation for Aging Research “Exploring the Links Between Aging, Proline Cis/Trans

Isomerization, Proteotoxicity, and Neurodegeneration” [PI: Dickey] 7. CurePSP “Impact of Arginase1 overexpression ” [PI: Lee] 8. Foundation for Angelman Syndrome Therapeutics “Identification and Characterization of Novel

Therapeutics for Angelman Syndrome” [PI: Weeber] 9. Lundbeck, Inc. “Monocyte Recruitment Inhibition Using C5aR Antibody in Transgenic Mouse Models

with Alzheimer-Like Pathology” [PI: Gordon] 10. Michael J Fox Foundation for Parkinson’s Research “Modulation of Microglial Activation” [PI: Nash] 11. Michael J Fox Foundation for Parkinson’s Research “Validation of SAT1 and Polyamine” [PI: Nash] 12. Thome Memorial Foundation “Histone deacetylase-6 inhibition as a treatment for tauopathy” [PI:

Morgan]


Alzheimer’s Clinical Center

The Alzheimer’s Clinical Center consists of the first and second floor outpatient clinics of the Byrd Alzheimer’s

Institute, including the Suncoast Alzheimer's Center and the Center for Memory C.A.R.E. It is directed by

Amanda G. Smith, MD.

In 2012-13, the clinics increased the number of both new and follow up patient visits. Most notably, the total

number of visits per provider has increased steadily for the last 3 years. In addition to the many local patients

we serve, we have had a growing number of visits from across the state. We also have had increasing numbers

of out-of-state residents coming to Tampa specifically for evaluation at the Byrd Institute. We have also, in the

last twelve months, seen patients travel to us from the Caribbean, Central and South America, Canada, England,

the Middle East, India, and Korea.

Center for Memory C.A.R.E. (Clinical Assessment, Research and Education)

Within the Center for Memory C.A.R.E. located on the second floor, we implemented a multi-specialty diagnostic

clinic for initial, comprehensive memory evaluations. During one of these visits, patients have a general health

examination by a geriatrician, a neuropsychological assessment, a medication review by a geriatric pharmacist, a

detailed memory evaluation by a geriatric psychiatrist, and a session with a licensed clinical social worker. These

half-day sessions were initially offered for 1-2 patients one day a week, and we have increased the number to 5

patients per week due to increasing demand.

Over the last year we have also expanded our services within the second floor C.A.R.E. center. They now include

a library with computer kiosks linked to Institute-approved information regarding Alzheimer’s disease. Recently

we have added an Occupational Therapist to our staff for providing assessment of driving ability, risk of falling,

and capacity for independent living. We also now have a Skype-based Elder law attorney who has donated

services to prepare power of attorney and health care surrogate documents at no cost to our patients.

Eric Pfeiffer PET Imaging Center

The PET Imaging center continues a steady increase with our brain and oncology PET services, with support from

both within USF and our local community. In addition, we have had significant growth with our PET research trial

enrollment and currently are participating in more than ten studies. We continue to provide Amyloid brain PET

imaging services to those who can afford to pay out-of-pocket, and we are optimistic that Medicare and other

insurance carriers will move forward towards reimbursement due to supported evidence-based imaging within

the last year. Our patients continue to share positive feedback of our facility and the specialized, individual

attention by our staff.

In January 2014, we hired an additional PET technologist to share a position between PET imaging and research

support specialist. This position reflects our significant growth in both clinical trial participation and in our PET

department, including Amyloid, brain and oncology imaging services.


Alzheimer’s Clinical Center Statistics

2011/2012 2012/2013 2013/2014

New patient visits to Suncoast Alzheimer's Center 386 329 529

Follow-up visits Suncoast Alzheimer's Center 1,388 1,679 1,489

C.A.R.E. visits (opened 2012) 104 251 262

Imaging visits (opened 2012, diagnostic) 100 267 289

Occupational Therapy visits (opened Sept 2013) 203

Driver Skill Evaluation visits (opened Sept 2013) 44

Clinical trial visits 654 200 274

Memory Disorders Clinic visits 1,228 941 73

Total patient visits 3,860 3,667 3,163

*Services billed

$ 793,293 $ 1,569,902 $ 1,662,624

Contractual adjustments

$ 481,564 $ 924,717 $ 972,057

Bad debt $ 1,329 $ 4,665 $ 18,280

Payments received $ 310,401 $ 640,520 $ 671,899

*Services billed represents only those charges associated with Suncoast Alzheimer’s Center clinical activity as this patient services revenue is credited to the USF Health Byrd Alzheimer’s Institute. The USF Memory Disorders Clinic patient services revenue is credited to the Department of Psychiatry and Behavioral Medicine within the College of Medicine.


Education

Education and training is a vital part of the institute and reaches healthcare professionals, Alzheimer's disease

caregivers, students and the community. The educational activities support the mission of the institute- to

disseminate information about Alzheimer's and memory loss; to increase the skill level and aptitude needed to

effectively care for individuals with Alzheimer's; to support family caregivers and to educate the next generation

of clinicians, researchers and educators.

Graduate Education and Research Training

Biomedical Sciences Graduate Students

Although not an academic program home, the institute participates in the training of post-baccalaureate

biomedical sciences degree-seeking students through the Discovery Research Laboratories. Institute faculty

participate in courses for both Ph.D. and M.S. students covering topics in Neuroscience, Pharmacology,

Physiology, Experimental Design, Molecular Biology and Biochemistry. Graduate students from the College of

Medicine and the School of Aging Studies conduct dissertation research at the institute and participate in a

variety of academic enrichment programs such as the institute seminar series, journal club and research

symposia. The Discovery Research laboratories have 35 continuing graduate students and approved four

individuals to receive the Ph.D. degree in academic year 2013/2014.

Post-doctoral Training

Clinical and laboratory research fellows choose to continue their specialized training in preparation for

independence at the institute because the environment is innovative, integrated and collaborative. Fifteen post-

doctoral fellows trained under Institute faculty during academic year 2013/2014.

Undergraduate and High School Student Training

Although the College of Medicine has few courses instructing undergraduates, the institute trains a number of

undergraduate students in biomedical research skills. Students in the Honors program develop thesis projects in

Institute laboratories under the guidance of institute investigators. Other students obtain independent study

credit or simply volunteer to gain research experience. Still others work as part-time research technicians or

complete their degree internships with our professional education and social support staff. Enterprising high

school students also find their way into research laboratories to gain experience and work on laboratory skills

and science fair projects. In 2013/2014, 97 undergraduate students and 37 high school students participated in

research at the Alzheimer’s Institute.


Healthcare Professionals

The clinicians and caregiving experts at the institute have created a portfolio of educational training programs

and materials designed to meet the needs of professionals involved in the care of individuals with Alzheimer's

and other dementias, as well as their caregivers. The training content provides the knowledge and practical skills

necessary to provide quality care to those with dementia.

Our professional education is designed to meet the educational needs of a diverse audience of healthcare

professionals including physicians, nurse practitioners, nurses, certified nursing assistants, social workers,

nursing home and assisted living facility administrators, care managers, professional guardians, mental health

counselors, pastoral care nurses, psychologists, ombudsmen and gerontologists. With the addition of the

occupational therapy services at the institute and expertise in the therapeutic intervention for Alzheimer's, we

have added occupational therapists to our audience of healthcare providers and have become accredited

through the Florida Board of Occupational Therapy to provide continuing education credit.

The health professionals trained represent diverse settings including assisted living facilities, nursing homes,

home health care, primary care practice, hospitals, hospice, adult day care, rehabilitation facilities and private

practice.

The institute conducts continuing education workshops, presents at community wide conferences and offers

customized training for professional organizations and healthcare staff at assisted living facilities, home health

care agencies and hospitals.

We are approved by the following organizations as an accredited provider of continuing education in Florida:

Florida Board of Nursing

Florida Board of Clinical Social Work, Marriage and Family Therapy and Mental Health Counseling

Florida Board of Nursing Home Administrators

Florida Board of Occupational Therapy

Assisted Living Administrators

Care Managers

Professional Guardians

Certified Nursing Assistants

Ten education programs were presented reaching more than 500 healthcare providers. We developed and conducted training

for the staff at Assisted Living Facilities in Tampa, Largo, Clearwater, Sarasota and Deland, FL; conducted two half day workshops

in Tampa at the USF Health Byrd Alzheimer's Institute; Presented at the Hillsborough County Elder Justice Committee, and the

Retired Nurses Association in the Villages to name a few.

Our monthly tours and lecture also attract health care providers from throughout Tampa Bay who want to learn more about

Alzheimer's diagnosis and research.


During this year we expanded the geographic area we provided training, both in Florida and nationally. We conducted a six week

continuing education national webinar on understanding Alzheimer's disease, behavior management and occupational therapy

interventions for dementia patients. The audience for the live webinars included nurses, occupational therapists and long term

care staff and administrators from across the country. The webinar is available on line for continuing education credit through

Academy Medical, and it is their only course offering on dementia. A training program was conducted on strategies for managing

behaviors with individuals with Alzheimer's for healthcare providers and caregivers at Tanglewood Manor in Jamestown NY.

Training was conducted for the assisted living, nursing home and home health staff at John Knox Village of Central Florida in

Deland Florida.

Geriatric Institute

The institute conducts a 3-day continuing education seminar every June for long term care administrators,

nurses, social workers, guardians, mental health counselors, care managers and others in the field of aging. Now

in its 16th year, this conference is very well recognized in the aging network and the evaluations consistently rate

the seminar excellent for content and speakers. The seminar focuses on Alzheimer's disease and other

dementias and also includes other practitioners from USF Health on topics pertaining to critical issues in

geriatrics. The 3-day program averages more than 100 participants from the Tampa Bay area and more than 20

businesses that pay to exhibit. This conference has been an excellent source of referrals and networking for

future program collaboration. This year’s program had a total of 185 participants, some from as far as

Tallahassee, which has made it necessary to secure a new location that is able to accommodate a larger

audience and allow us to expand this to a statewide program in 2015.

Continuing Medical Education for Physicians

This past year the Byrd Institute hosted a special accredited Physician Continuing Medical Education Program to

members of the Bay Area Medical Association, comprised of 150 African-American physicians throughout Tampa

Bay. Physicians learned best practices for the diagnosis and treatment of dementia including newly available

diagnostic imaging techniques and medication management for patients with early onset Alzheimer’s.

Family Caregivers

Caregiver Education

Providing education and support for caregivers is a priority of the institute and several educational programs

were conducted during this year to reach family caregivers.

Support Groups

Four monthly support groups are held in the building and led by faculty at the institute with a range of 4-20

participants attending each monthly meeting. The four support groups are:

for caregivers of individuals with Alzheimer's

for caregivers of individuals with Lewy body dementia

for individuals with loved ones with Mild Cognitive Impairment


for individuals who have memory loss or have recently been diagnosed with Alzheimer's

Presentations at community support groups

Institute faculty are requested to present at community based support groups and discuss behavior

management , communication techniques, medication management and research updates. Presentations were

given at the support groups at John Knox Village in Tampa, Emeritus Senior Living, and the Samaritan

Alzheimer's support group in Sun City Center to name a few. This initiative reached over 100 caregivers and

resulted in referrals to the CARE center, our clinical trials and our caregiver seminars.

Caregiver Seminars

Eight Caregiver seminars were conducted during this period throughout Florida, including Ocala, Deland, St.

Petersburg, Spring Hill, Largo, Sun City Center and Tampa reaching more than 600 caregivers. The day-long

seminars target family caregivers who are caring for a loved one with Alzheimer’s or other dementias in the

home or an assisted living facility. The feedback from the participants is overwhelmingly positive and many have

been caregivers for years with little or no education or support.

There are multiple benefits of this program including the opportunity to collaborate with community based

health care groups as sponsors of the seminar; to promote the services of the institute to caregivers and to

increase the knowledge and skills of family caregivers.

Community Education

Each year the Byrd Institute engages the community to educate people on the benefits of memory screening

and early diagnosis; the warning signs of Alzheimer’s and dementia; caregiver issues; pharmacological issues

affecting memory; Alzheimer's diagnosis, treatment and research through a variety of activities such as monthly

tours, offsite community talks, health fairs and conferences. During fiscal year 2014, the Byrd Institute continued

its goal to identify and establish relationships with new community groups and professional organizations. The

institute developed a new community alliance with the Brevard Alzheimer’s Foundation based in Melbourne, FL,

and is featured in their Purple Balloon Alzheimer’s Awareness Center. This collaboration is helping to educate

residents of Brevard County on current clinical studies in Alzheimer’s and resources to support caregivers coping

with the disease. We continue to provide similar education in The Villages, Sun City Center, East Tampa and

Lakeland through existing partnerships.

The institute held health events and educational activities such as the first annual Senior Safety and Falls

Prevention Day and National Memory Screening Day. To recognize Falls Prevention Awareness Month

(September) and shed light on older adult falls, the Byrd Institute offered free balance screenings, vision

screenings and home safety tours to the community inside the Functional Assessments and Rehabilitation

Center. A licensed occupational therapist provided a presentation on the benefits of occupational therapy in

falls prevention, and strategies older adults can use to reduce the risk of falls inside and outside the home.

Each November, the Institute shuts down clinic operations to offer free memory screenings and other important

health assessments to the community. The Institute collaborated with several departments in USF Health to


provide additional health screenings including balance, vision, hearing and medication reviews. The day-long

event attracted more than 200 guests in 2013.

New Initiatives and Programs

Institute faculty participated in the first AlzTalk seminar in Largo in collaboration with Elder Law Attorney, Sean

Scott. The dynamic day-long program was formatted after the well-known TED Talks and the four presentations

are now available on U-Tube.

As part of the Promising Innovations Grants funded by the Kendal Charitable Trust, the institute completed the

implementation of a Community-Based Memory Screening Program in East Tampa. The culmination of the

project was the development of a comprehensive guide for implementing community memory screening

programs. The guide contains all necessary components to plan and implement community based memory

screening including a video training, content information substantiating the need and benefits of memory

screening, a PowerPoint presentation for training screeners, screening forms with detailed instructions,

educational handouts, promotional materials and an evaluation.

As the aging population increases so does the prevalence of Alzheimer's and the need for assisted living facilities

specifically designed for memory care. The education division now provides individualized consultation with long

term care corporations, architects and design firms on the design and components of the physical environment

best suited to meet the cognitive and physical changes and challenges of Alzheimer's residents.

Academy Medical Systems has been a leader in continuing education for the healthcare industry since 1979.

They contacted the institute during this reporting period requesting a six-session webinar on Alzheimer's for

their healthcare constituency. Academy Medical webinars feature experts in their field and can be viewed live,

or recorded to meet the growing demand for flexible continuing education. As a result of the success of this

series, the institute will continue to conduct webinars to reach a broader based audience of healthcare

providers.

Dissemination of Educational Material

In addition to live talks, education was provided by the dissemination of educational material. The USF Health

Byrd Alzheimer's Institute Alzheimer's Caregiver Education Resource Library is available to caregivers, healthcare

professionals, students and the community at large. The education division of the institute continually

replenishes the holdings in the library and responds to phone, email, US mail and in-person requests for

information. The educational publications produced by the institute were re-designed as “Byrd Briefs,” an easy

to read trifold format on key topics pertaining to Alzheimer's.

New educational material was developed during this period to now include publications on home safety for the

Alzheimer's individual, medication issues, fall prevention, behavior management, and coping with caregiver

stress.


Business Operations

Institute Organization Chart

USF PRESDIENT

VP USF Health

USF Health Byrd Institute

CEO

Associate Institute Director and COO

Medical DIrector

Scientific Director

Accounting and Human Resources

Marketing and Communications

Education

Discovery LabsFaculty & Staff

Patient Service Faculty & Staff

Clinical ResearchFaculty & Staff

Development Officer

Maintenance Supervisor

Maintenance Staff

Board of Directors

Scientific Advisory Board

New Business Development

Individuals Appointed to the institute Board of Directors Chairman of the Board Sherrill M. Tomasino

Vice Chairman Eric Pfeiffer, MD

Members Mary M. Barnes Johnnie B. Byrd, Jr., JD John M. Hehn, Jr. Karen Holbrook, PhD Frank L. Morsani

Individuals Appointed to Leadership Roles within the institute

Chief Executive Officer Dave Morgan PhD

Associate Institute Director Jessica Banko, PhD, MS

Medical Director Amanda Smith, MD

Scientific Director Edwin Weeber, PhD


Communications and Marketing

The Communications and Marketing Team at the Byrd Institute engages in strategic initiatives and tactics to

strengthen the institute’s brand, and increase public awareness of clinic services, scientific research and

caregiver support services.

Brand Identity

To further solidify the ‘Byrd’ brand, the institute successfully secured a registered trademark in fiscal year 2013

of its tagline “…until Alzheimer’s is memory®,” and is currently pursuing a trademark for the “flying B” design

mark—which now serves as the official symbol for the Byrd Alzheimer’s Institute. The institute now has an

inventory of branded promotional items to coincide with printed brochures, flyers and pamphlets on patient

services. Branded promo materials include: license plate frames, purple stress brains, magnetic staff name

badges, lapel pins, and clipboards.

Physician Relationship Building

In order to obtain new patient referrals, the Byrd Institute routinely communicates with Tampa area physicians

through direct mailings on patient services, and clinic updates and news. The institute maintains a

comprehensive mailing list of over 200 medical physicians from varied disciplines and specialties. Each year on

Doctors’ Day (March 30th), the institute sends out a special postcard to over 250 physicians at USF Health and in

the community thanking them for their clinical service. In fiscal year 2013, the institute developed a clipboard

promoting PET/CT imaging that was shared with physicians to display in their medical offices.

Social Media

In April 2014, the Byrd Institute established a Twitter account with its first tweet, “…until Alzheimer’s is a

memory.” To-date, the institute has 49 Twitter followers. The Byrd Institute Facebook currently has 527

fans/followers, an increase of 20 percent over FY2012. The Constant Contact email marketing service has seen a

steady increase of subscribers with 744 active contacts—a 31 percent increase over the previous fiscal year. The

newsletter continues to attract an average email “open rate” of 40 percent, and a 20 percent average “click-

through” rate.

Print Media

In fiscal year 2013, the Byrd Institute renewed its annual Ad space in the Senior Living Guide (Fall/Winter 2014-

2015 edition), and purchased an Ad in the Alzheimer’s Family Organization, 10th Annual Fashion Show program

booklet. The Brain Research Discoveries magazine fall and spring issues were published October 2013 and April

2014. The magazine has over 3,500 subscribed readers locally and across the US. In future issues, the institute

will include a ‘Patient Experience’ profile to highlight the stories of the caregivers of clinic patients, and allow

readers to gain insight on what it’s like to live with Alzheimer’s disease from the patient/caregiver perspective.


SPRING 2014

Feature: Hollywood actors Seth Rogen and Lauren Miller using their star power in the fight against Alzheimer’s disease

Feature: Scientist Dr. Dan Lee hopes to advance treatment for Alzheimer’s and Parkinson’s diseases

Feature: Boosting brainpower for safer driving, successful aging

FALL 2013

Feature: Dr. Marcia Gordon: Identifying therapies to help prevent symptoms of Alzheimer’s

Feature: Coconut oil: A boost for faltering brain cells?

Feature: Q & A with Jennifer Bogush, AS, CNMT, certified nuclear medicine technologist

Public Relations

The USF Health Byrd Institute works closely with the USF Health Office of Communications and Marketing to

generate news releases and respond to incoming media inquiries. Among the most notable stories this fiscal

year were:

The Tampa Tribune ‘Who will care for an aging generation?’

MyFOX Tampa Bay ‘Dr. Jo's super foods series: Coconut’

The Tampa Tribune ‘Support essential for the Alzheimer’s caregiver’

USF Health News ‘Age-related research highlighted during NIA director’s visit to USF’

USF Health News ‘Stress-related protein speeds progression of Alzheimer’s disease’

USF Health News ‘David Morgan appointed to state Alzheimer’s Disease Advisory Committee’

CTV News (Canada) ‘U.S. study looks into the benefits of coconut oil on patients with Alzheimer's’

USF Health News ‘USF PhD graduate in neuroscience to join laboratory of new Nobel Prize winner’

FL Business Observer ‘Memory Lane’

Fairfield-Sun (Connecticut) ‘’Angels’ fight to find cure for rare genetic disorder’

The Tampa Tribune ‘Investment in research failing to keep pace with scope of Alzheimer’s (Commentary)’

EmaxHealth ‘Coffee May Save Eyesight and 4 More Surprising Benefits’

Research at USF Health ‘Neuroscientist shares insights on learning and memory at TEDx TampaBay’

The Washington Post ‘Why all the fuss about coconut?’


Development

Development is identified as a major priority for the institute and a dedicated development officer works collaboratively

with current staff, development volunteers and community members to gain their support for development efforts. The

development program at the institute encompasses annual, special and major giving efforts. Mid-way through the year

our Development Officer was promoted into the director position within the College of Nursing at USF Health. An active

search is underway for a new development officer.

2014 Development Program Highlights

Brain Research Discoveries magazine article featuring actors Seth Rogen and wife Lauren Miller, and their

support of the Byrd Institute and campaign to raise awareness of Alzheimer’s to the younger generations.

Faculty/Staff campaign culminated in 36% participation

Hosted USF Town & Gown Luncheon and Tour with approximately 40 guests

Alzheimer’s & the Arts fundraiser event to showcase the arts and how they improve the lives of those with

Alzheimer’s. The event included an online auction, entertainment by Byrd Institute faculty and a special

performance by jazz pianist and singer Lillette Jenkins-Wisner—who was diagnosed with Alzheimer’s at the Byrd

Institute.

Development Statistics

2011/2012 2012/2013 2013/2014

BYRD INSTITUTE ENDOWMENT

Principle value $ 4,616,578.94 $ 5,386,508.47 $ 5,478,384.00

*Endowment return 1.1% 13.1% 19.5%

Market value $ 5,517,597.30 $ 6,697,229.12 $ 7,643,015.00

ENDOWMENT SPENDABLE EARNINGS

Beginning balance $ 510,292.96

Deposits $ 302,985.16

Expenditures and transfers $ 245,343.16

Current balance $ 567,934.96

OPERATING FUNDS

Beginning balance $ 867,079.65 $ 884,399.54 $ 1,740,334.00

Spendable gifts $ 354,666.65 $ 1,213,465.40 $ 437,521.00

Earnings $ 375.21 $ 0 $ 0

Expenditures and transfers $ 337,721.93 $ 355,531.25 $ 347,150.00

Current balance $ 884,399.59 $ 1,742,333.69 $ 1,830,705.00

PLEDGED FUNDS

State match $ 0 $ 0 $ 0

Pledged gifts $ 13,077.77 $ 8,499 $ 0 *Endowments established for the benefit of the institute are invested in the USF Foundation’s long term Endowment pool. The primary long term investment objective of the endowment is to preserve the intergenerational equity of endowed gifts in order to provide a consistent source of funding for the programs supported by the endowment. These returns represent the 1 year return as of June 30

th for the Foundation’s Endowment pool.


Faculty Achievement

Peer-Reviewed Publications by Institute Faculty in Fiscal Year 2014 1. Ari C, Borysov SI, Wu J, Padmanabhan J, Potter H. Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces

neurotrophin and/or transmitter receptor function. Neurobiol Aging. 2014 Aug;35(8):1839-49. doi: 10.1016/j.neurobiolaging.2014.02.006. Epub 2014 Feb 10. PubMed PMID: 24636920; PubMed Central PMCID: PMC4084549.

2. Blair LJ, Nordhues BA, Hill SE, Scaglione KM, O'Leary JC 3rd, Fontaine SN, Breydo L, Zhang B, Li P, Wang L, Cotman C,

Paulson HL, Muschol M, Uversky VN, Klengel T, Binder EB, Kayed R, Golde TE, Berchtold N, Dickey CA. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. J Clin Invest. 2013 Oct 1;123(10):4158-69. doi: 10.1172/JCI69003. Epub 2013 Sep 3. PubMed PMID: 23999428; PubMed Central PMCID: PMC3784538.

3. Blair LJ, Zhang B, Dickey CA. Potential synergy between tau aggregation inhibitors and tau chaperone modulators.

Alzheimers Res Ther. 2013 Sep 16;5(5):41. doi: 10.1186/alzrt207. eCollection 2013. Review. PubMed PMID: 24041111; PubMed Central PMCID: PMC3979086.

4. Brownlow ML, Joly-Amado A, Azam S, Elza M, Selenica ML, Pappas C, Small B, Engelman R, Gordon MN, Morgan D.

Partial rescue of memory deficits induced by calorie restriction in a mouse model of tau deposition. Behav Brain Res. 2014 Sep 1;271:79-88. doi: 10.1016/j.bbr.2014.06.001. Epub 2014 Jun 9. PubMed PMID: 24925454.

5. Brownlow ML, Benner L, D'Agostino D, Gordon MN, Morgan D. Ketogenic diet improves motor performance but not

cognition in two mouse models of Alzheimer's pathology. PLoS One. 2013 Sep 12;8(9):e75713. doi: 10.1371/journal.pone.0075713. eCollection 2013. PubMed PMID: 24069439; PubMed Central PMCID: PMC3771931.

6. Cao C, Li Y, Liu H, Bai G, Mayl J, Lin X, Sutherland K, Nabar N, Cai J. The Potential Therapeutic Effects of THC on

Alzheimer's Disease. J Alzheimers Dis. 2014 Jan 1;42(3):973-84. doi: 10.3233/JAD-140093. PubMed PMID: 25024327.

7. Divekar SD, Burrell TC, Lee JE, Weeber EJ, Rebeck GW. Ligand-induced homotypic and heterotypic clustering of

apolipoprotein E receptor 2. J Biol Chem. 2014 Jun 6;289(23):15894-903. doi: 10.1074/jbc.M113.537548. Epub 2014 Apr 22. PubMed PMID: 24755222; PubMed Central PMCID: PMC4047363.

8. Filonova I, Trotter JH, Banko JL, Weeber EJ. Activity-dependent changes in MAPK activation in the Angelman

Syndrome mouse model. Learn Mem. 2014 Jan 16;21(2):98-104. doi: 10.1101/lm.032375.113. PubMed PMID: 24434871; PubMed Central PMCID: PMC3895224.

9. Gulick D, Chau DT, Khokhar JY, Dawson R, Green AI. Desipramine enhances the ability of risperidone to decrease

alcohol intake in the Syrian golden hamster. Psychiatry Res. 2014 Aug 30;218(3):329-34. doi: 10.1016/j.psychres.2014.04.038. Epub 2014 May 4. PubMed PMID: 24836200.

10. Jeon JP, Roh SE, Wie J, Kim J, Kim H, Lee KP, Yang D, Jeon JH, Cho NH, Kim IG,Kang DE, Kim HJ, So I. (2013). Activation

of TRPC4β by Gαi subunit increases Ca2+ selectivity and controls neurite morphogenesis in cultured hippocampal

neuron. Cell Calcium. 2013 Oct;54(4):307-19.

11. Jinwal UK, Groshev A, Zhang J, Grover A, Sutariya VB. Preparation and characterization of methylene blue

nanoparticles for Alzheimer's disease and other tauopathies. Curr Drug Deliv. 2014;11(4):541-50. PubMed PMID: 24237400.

http://www.ncbi.nlm.nih.gov/pubmed/24011658




12. Joly-Amado A, Brownlow M, Pierce J, Ravipati A, Showalter E, Li Q, Gordon MN, Morgan D. Intraventricular human immunoglobulin distributes extensively but fails to modify amyloid in a mouse model of amyloid deposition. Curr Alzheimer Res. 2014;11(7):664-71. PubMed PMID: 25115543.

13. Karagöz GE, Duarte AM, Akoury E, Ippel H, Biernat J, Morán Luengo T, Radli M, Didenko T, Nordhues BA, Veprintsev

DB, Dickey CA, Mandelkow E, Zweckstetter M, Boelens R, Madl T, Rüdiger SG. Hsp90-Tau complex reveals molecular basis for specificity in chaperone action. Cell. 2014 Feb 27; 156(5):963-74. doi: 10.1016/j.cell.2014.01.037. PubMed PMID: 24581495.

14. Lin D, De La Pena I, Lin L, Zhou SF, Borlongan CV, Cao C. The neuroprotective role of acupuncture and activation of

the BDNF signaling pathway. Int J Mol Sci. 2014 Feb 21;15(2):3234-52. doi: 10.3390/ijms15023234. PubMed PMID: 24566146; PubMed Central PMCID: PMC3958908.

15. Lin X, Bai G, Lin L, Wu H, Cai J, Ugen KE, Cao C. Vaccination induced changes in pro-inflammatory cytokine levels as

an early putative biomarker for cognitive improvement in a transgenic mouse model for Alzheimer disease. Hum Vaccin Immunother. 2014 Apr 21;10(7). [Epub ahead of print] PubMed PMID: 24751897.

16. O'Leary JC 3rd, Zhang B, Koren J 3rd, Blair L, Dickey CA. The role of FKBP5 in mood disorders: action of FKBP5 on

steroid hormone receptors leads to questions about its evolutionary importance. CNS Neurol Disord Drug Targets. 2013 Dec;12(8):1157-62. Review. PubMed PMID: 24040820.

17. Orwig SD, Chi PV, Du Y, Hill SE, Cavitt MA, Suntharalingam A, Turnage KC, Dickey CA, France S, Fu H, Lieberman RL.

Ligands for glaucoma-associated myocilin discovered by a generic binding assay. ACS Chem Biol. 2014 Feb 21;9(2):517-25. doi: 10.1021/cb4007776. Epub 2013 Dec 9. PubMed PMID: 24279319; PubMed Central PMCID: PMC3944078.

18. Roh SE, Woo JA, Lakshmana MK, Uhlar C, Ankala V, Boggess T, Liu T, Hong YH, Mook-Jung I, Kim SJ, Kang DE.

Mitochondrial dysfunction and calcium deregulation by the RanBP9-cofilin pathway. FASEB J. 2013 Dec;27(12):4776-89. doi: 10.1096/fj.13-234765. Epub 2013 Aug 27. PubMed PMID: 23982146; PubMed Central PMCID: PMC3834781.

19. Selenica ML, Davtyan H, Housley SB, Blair LJ, Gillies A, Nordhues BA, Zhang B, Liu J, Gestwicki JE, Lee DC, Gordon MN,

Morgan D, Dickey CA. Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation. 2014 Sep 3;11:152. doi: 10.1186/s12974-014-0152-0. PubMed PMID: 25183004; PubMed Central PMCID: PMC4167523.

20. Selenica ML, Alvarez JA, Nash KR, Lee DC, Cao C, Lin X, Reid P, Mouton PR, Morgan D, Gordon MN. Diverse activation

of microglia by chemokine (C-C motif) ligand 2 overexpression in brain. J Neuroinflammation. 2013 Jul 17;10:86. doi: 10.1186/1742-2094-10-86. PubMed PMID: 23866683; PubMed Central PMCID: PMC3726363.

21. Smith MC, Scaglione KM, Assimon VA, Patury S, Thompson AD, Dickey CA, Southworth DR, Paulson HL, Gestwicki JE,

Zuiderweg ER. The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex. Biochemistry. 2013 Aug 13;52(32):5354-64. doi: 10.1021/bi4009209. Epub 2013 Aug 2. PubMed PMID: 23865999; PubMed Central PMCID: PMC3856692.

22. Song S, Wang X, Sava V, Weeber EJ, Sanchez-Ramos J. In vivo administration of granulocyte colony-stimulating factor

restores long-term depression in hippocampal slices prepared from transgenic APP/PS1 mice. J Neurosci Res. 2014 Aug;92(8):975-80. doi: 10.1002/jnr.23378. Epub 2014 Mar 24. PubMed PMID: 24664800.

23. Stoner R, Chow ML, Boyle MP, Sunkin SM, Mouton PR, Roy S, Wynshaw-Boris A, Colamarino SA, Lein ES, Courchesne

E. Patches of disorganization in the neocortex of children with autism. N Engl J Med. 2014 Mar 27;370(13):1209-19. doi: 10.1056/NEJMoa1307491. PubMed PMID: 24670167.


24. Trotter J, Lee GH, Kazdoba TM, Crowell B, Domogauer J, Mahoney HM, Franco SJ, Müller U, Weeber EJ, D'Arcangelo

G. Dab1 is required for synaptic plasticity and associative learning. J Neurosci. 2013 Sep 25;33(39):15652-68. doi: 10.1523/JNEUROSCI.2010-13.2013. PubMed PMID: 24068831; PubMed Central PMCID: PMC3782631.

25. Trotter JH, Lussier AL, Psilos KE, Mahoney HL, Sponaugle AE, Hoe HS, Rebeck GW, Weeber EJ. Extracellular

proteolysis of reelin by tissue plasminogen activator following synaptic potentiation. Neuroscience. 2014 Aug 22;274:299-307. doi: 10.1016/j.neuroscience.2014.05.046. Epub 2014 Jun 2. PubMed PMID: 24892761.

26. Tyagi E, Fiorelli T, Norden M, Padmanabhan J. Alpha 1-Antichymotrypsin, an Inflammatory Protein Overexpressed in

the Brains of Patients with Alzheimer's Disease, Induces Tau Hyperphosphorylation through c-Jun N-Terminal Kinase Activation. Int J Alzheimers Dis. 2013;2013:606083. doi: 10.1155/2013/606083. Epub 2013 Sep 23. PubMed PMID: 24175110; PubMed Central PMCID: PMC3794555.

27. Wang R, Palavicini JP, Wang H, Maiti P, Bianchi E, Xu S, Lloyd BN, Dawson-Scully K, Kang DE, Lakshmana MK. RanBP9

overexpression accelerates loss of dendritic spines in a mouse model of Alzheimer's disease. Neurobiol Dis. 2014 Sep;69:169-79. doi: 10.1016/j.nbd.2014.05.029. Epub 2014 Jun 2. PubMed PMID: 24892886; PubMed Central PMCID: PMC4113832.

28. Woods NK, Padmanabhan J. Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated

cytotoxicity in pancreatic cancer cells. J Biol Chem. 2013 Oct 18;288(42):30114-24. doi: 10.1074/jbc.M113.459255. Epub 2013 Sep 10. PubMed PMID: 24022491; PubMed Central PMCID: PMC3798480.

29. Wu H, Li Y, Bai G, Niu Y, Qiao Q, Tipton JD, Cao C, Cai J. γ-AApeptide-based small-molecule ligands that inhibit Aβ

aggregation. Chem Commun (Camb). 2014 May 25;50(40):5206-8. doi: 10.1039/c3cc46685j. Epub 2013 Oct 25. PubMed PMID: 24158240.

Invited Presentations

1. Banko, J. Medical Innovation: How modern medicine delivers measurable benefits. Panel Speaker. Florida

Healthcare Affordability Summit, Orlando, FL Jan. 2014

2. Banko, J. Alzheimer’s disease: where we’ve been and where we are going. NARFEE Meeting. Plant City, FL Oct. 2013

3. Cao, C. Plenary Talk Award: 2014 International Conference on Complex Medical Engineering, Taibei, Taiwan 2014

4. Dickey, C. FKBP51 and tau. Max Planck Institute, Gottingen, Germany. Oct. 2013

5. Dickey, C. FKBP51 and tau. Utrecht University, Utrecht, Netherlands. Oct. 2013

6. Dickey, C. Tau and chaperones. University of Virginia, Jan. 2014

7. Dickey, C. FKBP51 in disease. University of Southern Alabama, Feb. 2014

8. Gordon M. Monocytes, Gene Therapy and Alzheimer’s Disease. University of South Florida, Tampa, FL Feb. 6, 2013

9. Kang, D. Molecular Biology and Therapeutic Targets of Alzheimer’s Disease and Related Disorders. International

Clinical Research Center, Brno, Czech Republic Sept. 2013

10. Kang, D. Molecular Intermediates of Neurodegeneration in Alzheimer’s Disease. Colorado State University, Fort

Collins, Colorado. Nov. 2013

11. Kang, D. Integration of Synaptic, Mitochondrial, and Cytoskeletal Changes in Alzheimer’s Disease Pathogenesis.

University of South Florida, Tampa, FL Feb 2014

12. Kang, D. Potential Mechanisms of Abeta-Tau Pathogenic Cascade in Alzheimer’s Disease. USF Molecular Medicine

Retreat, Tampa, Fl, Mar. 2014

13. Lee, D. Neuroinflammation, Arginine Metabolism, and Polyamines: Disorder, The Commander and Regulators of

Neuropathology. Florida A&M University Jun. 2014


14. Lee, D. Manipulations of Microglia During Aging and the Impact on Alzheimer’s Disease-like Pathology. USF College

of Medicine Oct. 2013

15. Morgan, D. New approaches to Alzheimer’s Disease; Prevention by 2020. NARFE National Convention Plenery

Speaker, Orlando, FL, Jul. 2013.

16. Morgan, D. Comments on the National Alzheimer’s Plan milestones. A Researchers perspective. Alzheimer’s

Association International Meeting, Boston MA. Jul. 2013.

17. Morgan, D. Aging and neurodegneration. Session Chairperson, BioFlorida annual meeting, Tampa FL Sept. 2013

18. Morgan, D. Alzheimer’s disease at the Byrd Institute, Charles University, Prague, Czech Republic Sept. 2013.

19. Morgan, D. A brief history of Alzheimer’s disease, CTSI, Brno, Czech Republic. Sept.

20. Morgan, D. Port insertin into muse jugular for long term monocyte delivery in mice. American Society of Veterinary

Surgery, Clearwater FL Sept. 2013.

21. Morgan, D. Geroscience. Testimony for U.S. Senate Select Committee on Aging, Washington DC Oct. 2013.

22. Morgan, D. New Approaches to preventing Alzheimer’s. Purple Balloon Reception, Brevard Alzheimer’s Foundation,

Melbourne FL Nov. 2013.

23. Morgan, D. Preventing Alzheimer’s by 2020. Eckard College Lifelong Learning Society, St Petersburg FL Nov. 2013

24. Morgan, D. Why we need more Alzheimer’s research funding. Alzheimer’s Association Delegates meeting. Chicago,

IL Nov. 2013.

25. Morgan, D. The Byrd Alzheimer’s Institute. A Translational Research Center. Grand Rounds in Neuroscience.

Michigan State University. Grand Rapids MI Dec. 2013.

26. Morgan, D. The role of amyloid and tau in Alzheimer’s disease. Nanoscience Institute, University of Central Florida,

Orlando FL. Dec. 2013

27. Morgan, D. Alzheimer’s 2020. Geriatric Case Managers Convention, St Petersburg, FL Jan. 2014.

28. Morgan, D. Research Update. 8th Annual Alzheimer’s Educational Seminar, Samaritans Alzheimer’s Auxiliary, Sun City

Center FL Mar. 2014.

29. Morgan, D. Alzheimer’s Disease. Past. Present and Future. AlzTalk 2014. Largo FL Apr. 2014.

30. Morgan, D. Preventing Alzheimer’s by 2020. Greater Indiana Alzheimer’s Association, Indianapolis IN Apr. 2014.

31. Morgan, D. Fractalkine and Arginase 1 expression reduce the tau phenotype in rTg4510 mice. 2nd International SFB

TRR 43 Symposium. Potsdam Germany May 2014.

32. Morgan, D. Cognitive Aging in Rodent Models and Humans. Glenn AFAR Symposium on Systemic aging. Santa

Barbara CA. Jun. 2014.

33. Padmanabhan, J. SILAC-based proteomic approach to determine role of APP in Alzheimer’s disease. Proteomics

Workshop; CMMB, USF, Tampa, FL Aug. 2013.

34. Padmanabhan, J. Functional role of amyloid precursor protein in neurodegeneration and oncogenesis. Wayne State

University, Detroit, MI, Nov. 2013.

35. Weeber, E. Understanding current Strategies for Angelman Syndrome. Angelman Syndrome Association of Spain

Conference, Madrid, Spain. Oct. 2013

36. Weeber, E. Angelman Syndrome Association Australia Conference, Sydney, Australia. (Keynote Speaker) Activity-

dependent changes in the Angelman Syndrome Mouse Model Nov. 2013

37. Weeber, E. From Benchtop to Bedside: Advances in Therapeutics Angelman Syndrome Association Australia

Conference, Sydney, Australia. (Keynote Speaker) Nov. 2013

38. Weeber, E. Silencing of the genes, a translation story of Angelman Syndrome. University of North Texas, Denton, TX.

Nov. 2013

39. Weeber, E. Advances in Angelman Syndrome Therapies. University of Miami, Miami, FL. Dec. 2013

40. Weeber, E. Current Advances in Angelman Syndrome Research Plenary Lecture Foundation for Angelman Syndrome


Therapeutics Global Summit & Gala. Dec 2013

41. Weeber, E. What we know about the human brain. TEDx, Tampa Bay Convention Center, Tampa, FL. May. 2014

42. Weeber, E. Using the AS mouse model to identify new therapeutics. & Update on AS clinical trial (U.S.). Angelman

Convention, Soest, Germany. Jun. 2014

43. Weeber, E. A Game of Neurons – understanding Human learning and memory. Pint of Science Festival, Tampa, FL.

May 2014

Conferences Attended by Institute Faculty in Fiscal Year 2014

1. Alzheimer’s Association International Conference, Boston, MA

2. Alzheimer’s Association International Conference, Copenhagen, Denmark

3. AD/PD International Conference, Florence, Italy

4. American Society for Neural Therapy and Repair, Clearwater Beach, FL

5. American Society of Veterinary Surgery, Clearwater FL

6. Angelman Convention, Soest, Germany

7. Angelman Syndrome Association Australia Conference; Sydney, Australia

8. Angelman Syndrome Association of Spain Conference, Madrid, Spain

9. Apolipoprotein Receptor Minisymposium, Lexington, KY

10. BioFlorida annual meeting, Tampa FL

11. Human Amyloid Imaging; Miami, FL

12. International Clinical Research Center and USF Health Alzheimer’s Institute Cooperative Agreement and Research

Collaboration Prague & Brno, Czech Republic

13. Society for Neuroscience; San Diego, CA

14. Florida Healthcare Affordability Summit, Orlando, FL

15. Foundation for Angelman Syndrome Therapeutics Global Summit, Chicago, IL

16. Foundation For Angelman Syndrome Therapeutics Australia Conference, Melbourne, Australia

17. Pint of Science Festival, Tampa, FL

18. Prolyl Isomerase Conference, Halle, Germany

19. TEDx, Tampa Bay Convention Center, Tampa, FL

20. 2nd International SFB TRR 43 Symposium, Potsdam, Germany

21. 19th Annual International Fall Stereology Workshop, San Diego, CA

22. 19th Annual Midwest Stress Response and Molecular Chaperone Meeting, Evanston, IL

23. 2014 International Conference on Complex Medical Engineering, Taibei Taiwan


News Media Interviews and Commentary by Institute Faculty and Staff in Fiscal Year 2014 1. Morgan, D. (2014, June). “Confronting Alzheimer’s horrors.” Tampa Tribune Editorial

2. Morgan, D. (2014, March). “Investment in research failing to keep pace with scope of Alzheimer’s.” Tampa Tribune

Editorial

3. Morgan, D. (2014, March). “Increased Alzheimer’s in Women.” Bay News 9 TV Interview

4. Morgan, D. (2014, Jan). “Letter to the Editor.” Sarasota-Herald Tribune

5. Morgan, D. (2013, Dec). “Live Radio Interview.” WSRQ Heidi Godman Show

6. Morgan, D. (2013, Jul). “Live Radio Interview - Update on Alzheimer’s.” WSRQ Heidi Godman Show

7. Morgan, D. (2013, Aug). “Interview on Alzheimer’s Disease.” CBC (Canada)

8. Poiley, E. (2014, Aug). “Brain Healthy Foods.” Villages Daily Sun

9. Poiley, E. (2014, Jan). “Memory Lane: Physical environment for Alzheimer's residents.” Florida Business Observer

10. Poiley, E. (2013, Aug). “Support essential for the Alzheimer’s caregiver.” The Tampa Tribune

11. Poiley, E. (2013, Sept). “Advice for Alzheimer's caregivers.” Jamestown Gazette

12. Poiley, E. (2013, Nov). “Benefits of Memory Screening.” WFLA News Radio Tampa, Corey Dylan

13. Weeber, E. (2014, Feb). ‘’Angels’ fight to find cure for rare genetic disorder” Connecticut Fairfield-Sun

14. Weeber, E. (2014, Apr). “Interview on new Autism Discovery” Bay News 9

15. Weeber, E. (2014, May). “Neuroscientist shares insights on learning and memory at TEDx TampaBay

16. Smith, A. (2013, Aug). “Interview on Alzheimer’s Disease.” CBC (Canada)

17. Smith, A., Morgan, D., Banko, J. (2013, Nov). “Transforming Alzheimer’s Care.” USF Magazine (Winter 2014)

18. Smith, A. (2014, June). “Alzheimer's study seeking 1,000 participants.” FOX13 (Tampa) TV Interview

19. Smith, A. (2014, July). “Alzheimer's study seeking 1,000 participants.” FOX6 (Alabama) TV Interview

20. Smith, A. (2014, May). “Why all the fuss about coconut?” Washington Post

21. Smith, J. (2013, July). “Dr. Jo's super foods series: Coconut.” FOX13 (Tampa) TV Interview

usf health yrd alzheimer [s institute page 1/media/files/byrd... · usf health yrd alzheimer [s...

Documents